Abstract:A novel style of versatile nano‐proteolysis targeting chimera is constructed by the incorporation of the BRD4 degrader dBET6, which aims to target both lung cancer cells and M2 tumor‐associated macrophages (TAMs) which favors the tumor‐promoting microenvironment. Specific degradation of BRD4 leads to substantial cell apoptosis of both lung cancer cells and TAMs, thereby remodeling the tumor microenvironment, which in turn, renders tumor shrinkage. This work proposes a novel approach for specifically delivering the BRD4 degrader to regress cancers. Recent evidence has indicated that overexpression of the epigenetic reader bromodomain‐containing protein 4 (BRD4) contributes to a poor prognosis of lung cancers, and the suppression of its expression promotes cell apoptosis and leads to tumor shrinkage. Proteolysis targeting chimera (PROTAC) has recently emerged as a promising therapeutic strategy with the capability to precisely degrade targeted proteins. Herein, a novel style of versatile nano‐PROTAC (CREATE (CRV‐LLC membrane/DS‐PLGA/dBET6)) is developed, which is constructed by using a pH/GSH (glutathione)‐responsive polymer (disulfide bond‐linked poly(lactic‐co‐glycolic acid), DS‐PLGA) to load BRD4‐targeted PROTAC (dBET6), followed by the camouflage with engineered lung cancer cell membranes with dual targeting capability. Notably, CREATE remarkably confers simultaneous targeting ability to lung cancer cells and tumor‐associated macrophages (TAMs). The pH/GSH‐responsive design improves the release of dBET6 payload from nanoparticles to induce pronounced apoptosis of both cells, which synergistically inhibits tumor growth in both subcutaneous and orthotopic tumor‐bearing mouse model. Furthermore, the efficient tumor inhibition is due to the direct elimination of lung cancer cells and TAMs, which remodels the tumor microenvironment. Taken together, the results elucidate the construction of a versatile nano‐PROTAC enables to eliminate both lung cancer cells and TAMs, which opens a new avenue for efficient lung cancer therapy via PROTAC.

Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors

Glutathione-dependent degradation of SMARCA2/4 for targeted lung cancer therapy with improved selectivity

Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects

Versatile Nano‐PROTAC‐Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy

Identification of Highly Efficacious PROTACs Targeting BRD4 Against Acute Myeloid Leukemia: Design, Synthesis, and Biological Evaluations

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression

Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells

Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor

Abstract 6049: Cell-based PROTAC screening for cancer drug discovery

Design, Synthesis, and Biological Evaluation of BRD4 Degraders.

PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

Design, synthesis, and biological evaluation of BRD4 degrader

Design and Synthesis of Proteolysis-Targeting Chimeras (protacs) As Degraders of Glutathione Peroxidase 4.

Cancer Selective Target Degradation By Folate-Caged Protacs

Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects

Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells

Proteolysis-targeting chimera against NR4A1 for cancer immunotherapy

Discovery of an Activatable Near-Infrared Fluorescent and Theranostic PROTAC for Tumor-Targeted Detecting and Degrading of BRD4

Development of Prostate Cancer-Targeting BRD4 Intramolecular Bivalent Molecular Glue Degraders